Year: 2019

Skyharbour Option Partner Orano Canada Commences Winter Diamond Drill Program at Preston Uranium Project

MotherlodeTV
V.SYH, Skyharbour, Uranium,

Skyharbour Resources Ltd. SYH)”>(TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) is pleased to announce that the Company’s option partner Orano Canada Inc. (“Orano Canada”) has commenced a planned 3,600 metre winter diamond drill program at the Preston Uranium Project. The project is located in the western Athabasca Basin near NexGen Energy Ltd.’s high-grade Arrow deposit hosted on its Rook-1 property and Fission Uranium Corp.’s Triple R deposit located within their PLS Project area. read more

MGX Minerals Announces Oilsands Lithium Extraction and Wastewater Treatment System Deployments

MotherlodeTV
CSE:XMG, MGX Minerals, lithium,

MGX Minerals Inc. (“MGX” or the “Company”) (CSE: XMG / FKT: 1MG / OTCQB: MGXMF) and engineering partner PurLucid Treatment Solutions (“PurLucid”) are pleased to report a second deployment of an advanced wastewater treatment system is near completion and commissioning is expected shortly. The system is capable of processing up to 10m3 per hour. The system will significantly reduce greenhouse gases through energy savings on steam generation. The technology provides superior treatment outcomes when compared to conventional technology which requires offsite trucking and high cost (due to toxicity) disposal. The technology can treat the water in line, under temperature and pressure, without cooling water first and is a paradigm shift advancement in waste water management and oilsands operations. This will result in significantly less energy use for water treatment, reduction in greenhouse gases and also eliminate a major operational challenge of a (“SAGD”) facility, which is heat exchanger fouling. read more

FSD Pharma Signs Collaboration and Profit-Sharing Agreement with Pharmastrip for Production and Delivery of Organic Medical Cannabis Infused in Oral Thin Film Strips

– FSD receives exclusive, perpetual license to manufacture and sell oral film strips in Canada
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the “Company), a licensed producer under the Cannabis Act, announced today that it has completed a strategic investment of $1.5 million in Pharmastrip Corp. and signed a definitive collaboration and profit sharing agreement with the company, effective January 23, 2019. Under the terms of the agreement, FSD will install Pharmastrip proprietary equipment at its facility in Cobourg, Ontario. FSD will use the equipment to manufacture organic medical cannabis infused in oral thin film strips. Pharmastrip will grant FSD an exclusive, perpetual license to manufacture and sell the oral thin film strips in Canada. read more

Goldplay announces its maiden mineral resource, containing 36 million oz AgEq (indicated) and 11 million oz AgEq (inferred), at the San Marcial Project

MotherlodeTV
V.GPLY, Goldplay Exploration, gold
Figure 1 Location Breccia and Stockwork Zone in the San Marcial Resource Area

Goldplay Exploration Ltd. (TSXV: GPLY, FRANKFURT: GPE, OTCQB: GLYXF) (“Goldplay” or the “Company”) is pleased to announce the completion of an independent NI 43-101 mineral resource estimation (“Mineral Resource”), for the San Marcial Project, located in Sinaloa, Mexico. Goldplay’s maiden San Marcial Mineral Resource is a substantial increase from the historical resource completed by Silvermex Resources Inc. in 2008 (“Historical Resource”)1 and reported by Goldplay on 18 April 2018. read more

FSD Pharma Announces Signing of LOI with Solarvest to Develop and Test Pharma-Grade Cannabinoids out of Algae

PHARMA GRADE PROCESS COULD REDUCE THE PRODUCTION TIME FOR TARGETED CANNABINOID MOLECULE(S
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (CSE: HUGE) (OTC:  FSDDF) (“FSD Pharma“) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest“) (collectively, the “Parties“), a technology company which has developed an algal-based flexible production platform capable of producing health products, are pleased to announce that they have signed a non-binding letter of intent (“LOI“). The parties intend to enter into a definitive agreement (the “Collaborative Research Agreement“), under which Solarvest would conduct research using its algal expression technology to develop pharma-grade cannabinoids (the “Project Cannabinoids“), the Parties would make mutual investments into one another, and Solarvest would grant FSD Pharma an exclusive license over a subset of the Project Cannabinoids and certain royalty rights over all of the other Project Cannabinoids. read more